Literature DB >> 10766830

Rho-A is critical for osteoclast podosome organization, motility, and bone resorption.

M A Chellaiah1, N Soga, S Swanson, S McAllister, U Alvarez, D Wang, S F Dowdy, K A Hruska.   

Abstract

Rho plays a regulatory role in the formation of actin stress fibers and focal adhesions, and it is also involved in integrin-mediated signaling events. To study the role of Rho in alpha(v)beta(3)/gelsolin-dependent signaling, the HIV-Tat peptide, hemagglutinin (HA)-tagged Rho(Val-14) (constitutively active) and Rho(Asn-19) (dominant negative) were transduced into avian osteoclasts. Protein transduction by HA-Tat was highly efficient, and 90-100% of the cells were transduced with HA-tagged proteins. We demonstrate here that Rho(Val-14) transduction (100 nM) stimulated gelsolin-associated phosphatidylinositol 3-kinase activity, podosome assembly, stress fiber formation, osteoclast motility, and bone resorption, mimicking osteoclast stimulation by osteopontin/alpha(v)beta(3.) The effects of Rho(Val-14) transduction stimulation was time-dependent. C3 exoenzyme blocked the effects of Rho(Val-14) and induced podosome disassembly, loss of motility, and inhibition of bone resorption. Transduction of Rho(Asn-19) produced podosome disassembly, and blocked osteopontin stimulation. These data demonstrate that integrin-dependent activation of phosphoinositide synthesis, actin stress fiber formation, podosome reorganization for osteoclast motility, and bone resorption require Rho stimulation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10766830     DOI: 10.1074/jbc.275.16.11993

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  74 in total

1.  Evaluation of strategies for the intracellular delivery of proteins.

Authors:  Dongjiu Ye; Dong Xu; Alex U Singer; R L Juliano
Journal:  Pharm Res       Date:  2002-09       Impact factor: 4.200

2.  Osteopontin inhibits mineral deposition and promotes regression of ectopic calcification.

Authors:  Susan A Steitz; Mei Y Speer; Marc D McKee; Lucy Liaw; Manuela Almeida; Hsueh Yang; Cecilia M Giachelli
Journal:  Am J Pathol       Date:  2002-12       Impact factor: 4.307

3.  Apatite-mediated actin dynamics in resorbing osteoclasts.

Authors:  Frédéric Saltel; Olivier Destaing; Frédéric Bard; Diane Eichert; Pierre Jurdic
Journal:  Mol Biol Cell       Date:  2004-09-15       Impact factor: 4.138

4.  Cdc42 regulates bone modeling and remodeling in mice by modulating RANKL/M-CSF signaling and osteoclast polarization.

Authors:  Yuji Ito; Steven L Teitelbaum; Wei Zou; Yi Zheng; James F Johnson; Jean Chappel; F Patrick Ross; Haibo Zhao
Journal:  J Clin Invest       Date:  2010-05-24       Impact factor: 14.808

5.  Phosphorylation of RhoGDI by Src regulates Rho GTPase binding and cytosol-membrane cycling.

Authors:  Céline DerMardirossian; Gabriel Rocklin; Ji-Yeon Seo; Gary M Bokoch
Journal:  Mol Biol Cell       Date:  2006-08-30       Impact factor: 4.138

Review 6.  Protein transduction technology.

Authors:  Masayuki Matsushita; Hideki Matsui
Journal:  J Mol Med (Berl)       Date:  2005-02-10       Impact factor: 4.599

7.  Osteoclastogenic activity and RANKL expression are inhibited in osteoblastic cells expressing constitutively active Gα(12) or constitutively active RhoA.

Authors:  Jun Wang; Paula H Stern
Journal:  J Cell Biochem       Date:  2010-12-15       Impact factor: 4.429

8.  Paxillin phosphorylation controls invadopodia/podosomes spatiotemporal organization.

Authors:  Cédric Badowski; Géraldine Pawlak; Alexei Grichine; Anne Chabadel; Christiane Oddou; Pierre Jurdic; Martin Pfaff; Corinne Albigès-Rizo; Marc R Block
Journal:  Mol Biol Cell       Date:  2007-11-28       Impact factor: 4.138

9.  Actin can reorganize into podosomes in aortic endothelial cells, a process controlled by Cdc42 and RhoA.

Authors:  Violaine Moreau; Florence Tatin; Christine Varon; Elisabeth Génot
Journal:  Mol Cell Biol       Date:  2003-10       Impact factor: 4.272

10.  Ameloblastin modulates osteoclastogenesis through the integrin/ERK pathway.

Authors:  Xuanyu Lu; Yoshihiro Ito; Phimon Atsawasuwan; Smit Dangaria; Xiulin Yan; Tuojiang Wu; Carla A Evans; Xianghong Luan
Journal:  Bone       Date:  2013-02-04       Impact factor: 4.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.